<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799212</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0129</org_study_id>
    <secondary_id>2016-004230-20</secondary_id>
    <nct_id>NCT02799212</nct_id>
  </id_info>
  <brief_title>Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma by Laparotomy</brief_title>
  <acronym>SOMAPROTECT01</acronym>
  <official_title>Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma by Laparotomy: Multicenter Randomized Double-blind Placebo Controlled Trial (SOMAPROTECT01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most patients undergoing hepatectomy for hepatocellular carcinoma (HCC) suffer from
      underlying liver disease and are exposed to the risk of postoperative ascites, with
      subsequent morbidity, liver and renal failure, the need for specific treatments and prolonged
      hospital stay. Postoperative ascites is favored by an imbalance between portal venous inflow
      and the diminished hepatic venous outflow. Finding a reversible, non-invasive method for
      modulating the portal inflow would be of interest: it could be used temporarily during the
      early postoperative course to prevent acute portal hypertension. Somatostatin, a well-known
      drug already used in several indications, may limit the risk of postoperative ascites and
      liver failure by decreasing portal pressure after hepatectomy for HCC in patients with
      underlying liver disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">April 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence of postoperative ascites during the postoperative course</measure>
    <time_frame>Day 90</time_frame>
    <description>The presence of postoperative ascites during the postoperative course defined by:
≥500 ml / 24h of fluid in the drains during at least 3 days. Or
ascites requiring puncture or drainage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ascites</measure>
    <time_frame>Day 90</time_frame>
    <description>Number of days with ≥ 500ml / 24h of ascites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of ascites</measure>
    <time_frame>Day 90</time_frame>
    <description>Total ascites volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative morbidity</measure>
    <time_frame>Day 90</time_frame>
    <description>Postoperative morbidity according to Dindo-Clavien</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity on Liver failure</measure>
    <time_frame>Day 90</time_frame>
    <description>Presence and severity of hepatic failure according to International Study Group of Liver Surgery (ISGLS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity on Renal failure</measure>
    <time_frame>Day 90</time_frame>
    <description>Presence and severity of renal failure according to RIFLE scale (RIFLE: Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion (50ml of 0.9% NaCl/day) during 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatostatin infusion</intervention_name>
    <description>postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo infusion</intervention_name>
    <description>Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HCC diagnosed by histology or by imaging findings according to the
             Barcelona Clinic Liver Cancer Group

          -  Patients with a single or multiple HCCs deemed to be resectable with a curative intent
             at the preoperative evaluation

          -  Patients for whom an indication for hepatectomy by open approach (laparotomy) has been
             decided and approved by multidisciplinary board

          -  Patients with any underlying liver disease with or without proven cirrhosis, regarding
             histological features (including F2-F3-F4 fibrosis with or without cirrhosis) or with
             other evidence of a diseased liver if no biopsy has been performed preoperatively
             (dysmorphic liver or evidence of portal hypertension at imaging findings, oesophageal
             varices at endoscopy)

          -  Age ≥ 18 years

          -  Patients with ability to understand and sign a written inform consent form

          -  Patients who will be available for follow-up

        Exclusion Criteria:

          -  Patients participating in another interventional research in progress or including an
             exclusion period still in progress at pre-inclusion (except interventional research
             with minimal risks and constraints that do not interfere with the judgement criteria
             of the study according to the judgement of the coordinating investigator).

          -  Patients with evidence of a healthy liver at biopsy

        Disease-associated non-inclusion criteria include:

          -  Another histologic type of hepatic tumor besides HCC

          -  Distant extra-hepatic metastases, including peritoneal carcinomatosis

          -  The existence of complete portal thrombosis of the main portal trunk

        Operative technique-associated non-inclusion criteria include:

        - Indication for laparoscopic approach
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kayvan Mohkam</last_name>
    <phone>+4 72 07 11 00</phone>
    <email>kayvan.mohkam@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solène Pantel</last_name>
    <phone>+33 4 26 73 27 25</phone>
    <email>solene.pantel02@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>APHP - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François CAUCHY</last_name>
      <email>françois.cauchy@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Francois CAUCHY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda KHOY-EAR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayvan Mohkam</last_name>
      <phone>+33 4 72 07 11 00</phone>
      <email>Kayvan.mohkam@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Solène Pantel</last_name>
      <phone>+33 4 26 73 27 25</phone>
      <email>solene.pantel@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Kayvan Mohkam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie GREGOIRE</last_name>
      <email>emilie.gregoire@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Emilie GREGOIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent REYDELLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut Lévèque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence CHICHE</last_name>
      <email>laurence.chiche@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence CHICHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédérique PRIEM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim BOUDJEMA</last_name>
      <email>karim.boudjema@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Karim BOUDJEMA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène BELOEIL</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice MUSCARI</last_name>
      <email>muscari.f@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice MUSCARI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre ROBERT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>Ascites</keyword>
  <keyword>Somatostatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

